(Q35652450)

9 August 2017

title

Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase (English)

1 reference

Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase

9 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

1 reference

corrigendum / erratum

0 references

Brian J Druker

9

0 references

Richard A. Larson

object named as

Richard A Larson

2

0 references

Hagop Kantarjian

1

object named as

Hagop M Kantarjian

1 reference

9 August 2017

8

Jorge Cortes

1 reference

9 August 2017

6

Marc Rudoltz

1 reference

9 August 2017

3

Francois Guilhot

1 reference

9 August 2017

5

Manisha Mone

1 reference

9 August 2017

Stephen G O'Brien

4

1 reference

9 August 2017

Tillmann Krahnke

7

1 reference

9 August 2017

International Randomized Study of Interferon and STI571 (IRIS) Investigators

10

1 reference

9 August 2017

language of work or name

English

0 references

publication date

1 February 2009

1 reference

9 August 2017

1 reference

9 August 2017

volume

115

1 reference

9 August 2017

issue

3

1 reference

9 August 2017

page(s)

551-560

1 reference

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

9 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Overriding imatinib resistance with a novel ABL kinase inhibitor

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

The effect of dose increase of imatinib mesylate in patients with chronic or accelerated phase chronic myelogenous leukemia with inadequate hematologic or cytogenetic response to initial treatment.

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

25 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4445370

15 November 2018

Identifiers

DOI

10.1002/CNCR.24066

1 reference

9 August 2017

1 reference

9 August 2017

1 reference